TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02816814

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diet rich in omega-3 fatty acids
Description: A diet rich in omega-3 fatty acids (7g/die) will be administered for 4 months to overwieght women in menopause

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Diet with extra virgin olive oil
Description: A diet rich in EVO (25-30g/die) will be administered for 4 months to overwieght women in menopause
Study: NCT05933811

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: exploratory laparoscopy
Description: Laparoscopic exploration for impalpable maldescended testis in pediatric age group
Study: NCT02826187

Intervention type: OTHER
Intervention: Early complications data
Description: Early complications of interest are :~* New arthroplasty for any reason~* Related to the implant :~  * Wrong position of the implant~ * Early displacement of the implant~* Related to the intervention :~  * Hematoma~ * Dislocation (or not causing the resumption of joint replacement)~ * Deep vein thrombosis~ * Pulmonary embolism~ * Acute Infection

Intervention type: OTHER
Intervention: Late stage complications data
Description: Late complications taken into account are:~* New arthroplasty for any reason~* Aseptic loosening~* Delayed hypersensitivity reaction type IV~* Solid Tumors~* Recurrent dislocation (causing or not the resumption of joint replacement)~* Allergic reactions of any kind~* Chronic infection

Intervention type: OTHER
Intervention: Patient Satisfaction
Description: Patient satisfaction evaluated by Womac reduced Score

Intervention type: OTHER
Intervention: Efficacity
Description: Efficacity as evaluated by Harris HIP score

Intervention type: OTHER
Intervention: Radiographic evaluation
Description: Bone reaction visible in radiography
Study: NCT02789982

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: β-adrenergic blocker propranolol

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as usual
Study: NCT01725152

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: oral suspension, given in 3 divided doses

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: oral suspension, given in 3 divided doses
Study: NCT03065712

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: F-18 Fluoroestradiol
Description: F-18 Fluoroestradiol will be administered for PET/CT scan.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo PET/CT
Study: NCT04694911

Intervention type: BEHAVIORAL
Intervention: Focus Group
Description: Participate in focus group

Intervention type: OTHER
Intervention: Interview
Description: Complete cognitive interview
Study: NCT03065712

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo PET/CT
Study: NCT04694911

Intervention type: OTHER
Intervention: Research or Clinical Assessment Tool
Description: Receive OOCAT
Study: NCT00796458

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: docetaxel
Description: Given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: releasing hormone agonist therapy
Description: Patients receive luteinizing hormone-releasing hormone analogue therapy until disease progression.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: releasing hormone agonist therapy
Description: Patients receive luteinizing hormone-releasing hormone analogue therapy until disease progression.
Study: NCT04316416

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: T7 Level Erector Spinae Plane Block
Description: ESP block is planned after the completion of surgery and before the extubation. Its application will be planned from the T7 level bilaterally when the patients are turned to the right lateral position. A linear ultrasound probe will be placed in the longitudinal parasagittal orientation 3 cm to lateral of T7 spinous process.~After imaging of erector spina musceles and transvers process of 7 th trorocal vertebrae, an ultrasound-guided local anaesthetic mixture ( 0.5% bupivacaine 15 cc + 2% lidocaine 5 cc) will be applied to the region between spinae muscles and transverse process using a needle of 22 gauge \& 8cm directed from cranial to caudal.~After application of the same procedure to the other side, the patients will be woken-up and patient-controlled analgesia consisting of intravenous morphine will be planned for all of them.~Additionally, at postoperative 1.,4.,8.,12.,24. hours, NRS scales and morphine consumption will be recorded.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: T9 Level Erector Spinae Plane Block
Description: ESP block is planned after the completion of surgery and before the extubation. Its application will be planned from the T9 level bilaterally when the patients are turned to the right lateral position. A linear ultrasound probe will be placed in the longitudinal parasagittal orientation 3 cm to lateral of T9 spinous process.~After imaging of erector spina musceles and transvers process of 9 th trorocal vertebrae, an ultrasound-guided local anaesthetic mixture ( 0.5% bupivacaine 15 cc + 2% lidocaine 5 cc) will be applied to the region between spinae muscles and transverse process using a needle of 22 gauge \& 8cm directed from cranial to caudal.~After application of the same procedure to the other side, the patients will be woken-up and patient-controlled analgesia consisting of intravenous morphine will be planned for all of them.~Additionally, at postoperative 1.,4.,8.,12.,24. hours, NRS scales and morphine consumption will be recorded.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: control group
Description: 24 hours morphine consumption will be recorded using the patient controlled analgesia device with intravenous morphine.
Study: NCT01357681

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: (2)-epigallocatechin-3-gallate (EGCG)
Description: Month 01:400 mg /day (200-0-200) Month 02:800 mg /day (400-0-400) Month 03 -12: 1200 mg /day (600-0-600)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT01593371

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: Metformin 1000 mg fixed dose, twice daily (500 mg tablets x 2)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pioglitazone
Description: Pioglitazone 30 mg fixed dose, twice daily (15 mg tablets x 2)
Study: NCT03738527

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranexamic Acid 100mg/mL, 20mL topical
Description: Drug: Tranexamic Acid~20 mL TXA (100 mg/mL injection solution, total 2g TXA) applied topically to the mastectomy cavity for 5 minutes before wound closure

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline Flush, 0.9%, 20mL topical
Description: Drug: Normal Saline~20 mL 0.9% NaCl (normal saline) applied topically to the mastectomy cavity for 5 minutes before wound closure
Study: NCT01980160

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Activated Nometex Device
Description: Nometex Device that is activated so will be sending electrical pulses to the median nerve which will travel through afferent nerve fibers to the emetic centers of the brain. It is in these areas that the neurotransmitters modulate signals going to the stomach via the Vagus nerve. These electrical signals normalize the stomach rhythms, thereby alleviating nausea and vomiting.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Unactivated Nometex Device
Study: NCT01569347

Intervention type: OTHER
Intervention: Interviews
Description: Interviews

Intervention type: OTHER
Intervention: Blood sample
Description: Blood sample

Intervention type: OTHER
Intervention: Hair sample
Description: Hair sample
Study: NCT02575339

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MLN0128
Description: Phase I Dose Escalation Study Cohort 1 MLN0128 15mg QW; Cohort 2 MLN0128 20mg QW; Cohort 3 MLN0128 30mg QW

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MLN0128 (RP2D)
Description: Phase II Arm A:~MLN0128 administered orally at the recommended phase II dose (RP2D) once weekly.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sorafenib
Description: Phase II Arm B:~Sorafenib administered at 400mg PO BID daily
Study: NCT02994251

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine
Description: 1000 mg/m\^2 of gemcitabine on Day 1 and 8, Dosages may be modified or delayed due to toxicities

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: 25 mg/m\^2 on Day 1 and 8, Dosages may be modified or delayed due to toxicities

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Conventional TACE (transarterial chemoembolization) with Doxorubicin/Mitomycin-C
Description: If conventional transarterial chemoembolization (TACE) is warranted based on MRI assessment and the patient meets all the eligibility criteria for TACE therapy, then cTACE will be scheduled to take place during Week 3 of that cycle. Patients will always receive the first cTACE for study; follow-up cTACE will occur on demand.
Study: NCT02257619

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itacitinib
Description: Itacitinib tablets administered orally at 400 mg QD for Part 1 of the study.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: docetaxel
Description: Administered as an intravenous infusion in the clinic at 75 mg/m\^2 Q3W for Part 1 of the study.
Study: NCT04260321

Intervention type: DEVICE
Intervention: AI
Description: Artificial intelligence colonoscopy
Study: NCT03065712

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study: NCT03284294

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cholecalciferol
Description: cholecalciferol 2000 IU oral daily for 8 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral placebo daily for 8 weeks
Study: NCT01968720

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CAT-2003

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Study: NCT04284982

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 16-week supervised heavy resistance training program with weekly undulating periodization
Description: Participants trained a whole-body program consisting of squat, bench press, deadlift and pendlay row two times per week for 16 weeks
Study: NCT02204241

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carfilzomib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Study: NCT01405846

Intervention type: DRUG
Group type: OTHER
Intervention: Gefitinib
Description: 250mg od for 6 months
Study: NCT02473133

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Personalized dose redistribution
Description: Patients will receive an individualized radiotherapy prescription up to a total dose of 74 Gy given in 6.6 weeks if they have a positive FDG-PET at 42Gy. An initial dose of 50 Gy will be delivered in 5 weeks (single daily fractions of 2 Gy), then an additional dose up to 24 Gy will be delivered over 1.6 week.

Intervention type: RADIATION
Group type: SHAM_COMPARATOR
Intervention: No personalized dose redistribution
Description: Patients will receive a single prescription of 66 Gy in 33 fractions in 6.6 weeks, with 2 Gy fractions given once daily, 5 days a week, without target volume reduction or adaptation (whatever the FDG-PET2 result).
Study: NCT00533637

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetirizine dihydrochloride (10 mg/ml) liposomal formulation
Description: 2x110μL in each nostril twice daily for 7 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cetirizine dihydrochloride (10 mg/ml) buffer solution
Description: 2x110μL in each nostril, as a single dose

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Citrate buffer with preservatives
Study: NCT03392753

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Mechanochemical ablation
Description: Treatment of incompetent saphenous veins using mechanochemical ablation (Clarivein)

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Cyanoacrylate adhesive
Description: Treatment of incompetent saphenous veins using cyanoacrylate (VenaSealTM)
Study: NCT01944969

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brexpiprazole
Description: 1, 2, or 3 mg/day, once daily dose, tablets, orally. Uptitration in weekly steps from 0.5 mg/day (patients ≥65) or 1 mg/day (patients 18-64 years)
Study: NCT04400409

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Intervention A - Vascular Care + site 6MWT administration
Description: Implementation of multiple strategies related to improving lipid management, starting with a referral to the vascular care team. The subject will undergo a visit with a vascular care team, including a Vascular Medicine specialist who will obtain a patient history and prescribe a lipid lowering therapy regimen. The subject will also meet with a pharmacist to answer questions related to access to medications, drug side effects, and potential interactions with the subject's other medications. Additionally, the site staff will conduct and guide the subjects through 6MWTs at protocol-dictated time points.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Intervention B - Standard Care + site 6MWT administration
Description: Consists of provision of the treating provider with a copy of the 2018 ACC/AHA Guidelines on the Management of Blood Cholesterol. Subjects will return at 6 and 12 months for lab draws and endpoint event assessments but will not meet with vascular care team. Additionally, the site staff will conduct and guide the subjects through 6MWTs at protocol-dictated time points.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Intervention A - Vascular Care + CPC EQuIP 6MWT administration
Description: Implementation of multiple strategies related to improving lipid management, starting with a referral to the vascular care team. The subject will undergo a visit with a vascular care team, including a Vascular Medicine specialist who will obtain a patient history and prescribe a lipid lowering therapy regimen. The subject will also meet with a pharmacist to answer questions related to access to medications, drug side effects, and potential interactions with the subject's other medications. Additionally, the CPC EQuIP team will conduct and guide the subjects through 6MWTs at protocol-dictated time points.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Intervention B - Standard Care + CPC EQuIP 6MWT administration
Description: Consists of provision of the treating provider with a copy of the 2018 ACC/AHA Guidelines on the Management of Blood Cholesterol. Subjects will return at 6 and 12 months for lab draws and endpoint event assessments but will not meet with vascular care team. Additionally, the CPC EQuIP team will conduct and guide the subjects through 6MWTs at protocol-dictated time points.
Study: NCT04179968

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 68Ga PSMA-11 injection
Description: Injection of 68Ga PSMA-11

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography/Computed Tomography
Description: PET/CT scan after 68Ga PSMA-11 injection
Study: NCT04652076

Intervention type: DRUG
Group type: OTHER
Intervention: Paclitaxel
Description: Standard Chemotherapy agent will be administred IV, Q3W, up to 6 cycles of treatment.

Intervention type: DRUG
Group type: OTHER
Intervention: Paclitaxel
Description: Standard Chemotherapy agent will be administred IV, Q3W, up to 6 cycles of treatment.

Intervention type: DRUG
Group type: OTHER
Intervention: Paclitaxel
Description: Standard Chemotherapy agent will be administred IV, Q3W, up to 6 cycles of treatment.

Intervention type: DRUG
Group type: OTHER
Intervention: Carboplatin
Description: Standard Chemotherapy agent will be administred IV, Q3W, up to 6 cycles of treatment.

Intervention type: DRUG
Group type: OTHER
Intervention: Carboplatin
Description: Standard Chemotherapy agent will be administred IV, Q3W, up to 6 cycles of treatment.

Intervention type: DRUG
Group type: OTHER
Intervention: Carboplatin
Description: Standard Chemotherapy agent will be administred IV, Q3W, up to 6 cycles of treatment.
Study: NCT04135378

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ascorbic acid
Description: Study Group :- ascorbic acid ( 500 mg per day) for one week before presentation

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: :- included 30 students given placebo for one week before presentation.
Study: NCT02813486

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Biological: GC3111 vaccine
Description: 0.5mL, Intramuscular

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Biological: Boostrix® vaccine
Description: 0.5mL, Intramuscular
Study: NCT04894318

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Low-fat and low-cholesterol diet
Description: Low-fat (\<30% of total energy) and low-cholesterol (\<200mg/day) diet total of 12 weeks
Study: NCT04639349

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: exercise group
Description: the exercise group (20 patients) will receive a exercise session contains a fifty minutes exercise training at home with moderate intensity on the available training devices as bicycle or treadmill in addition to 30 minutes of exercising of upper and lower limb, the session will be repeated three times per week for eight weeks.

Intervention type: OTHER
Group type: OTHER
Intervention: control group
Description: the control group will not be trained
Study: NCT01152190

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tadalafil
Description: Administered orally, once daily for 8 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered orally, once daily for 8 weeks
Study: NCT03052361

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ondansetron
Description: Patients allocated to this arm will receive ondansetron in the ED triage.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: similar looking and tasting liquid placebo
Study: NCT04242732

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: CT scan of the knee under weight-bearing with the Cone Beam Computed Tomography (CBCT) scanner system.
Description: The patient will be evaluated under weight-bearing, with knee flexed at 30 ° and therefore with contracted thigh muscles. The measurement and maintenance of the 30 ° of flexion will be controlled by a goniometer applied laterally to the knee and fixed by means of an elastic band.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Conventional CT scan
Description: The patient will be evaluated in supine position, with the muscles relaxed and the knee in full extension by conventional CT scan
Study: NCT03709693

Intervention type: DEVICE
Intervention: SternaLock Blu
Description: Sternal closure will be accomplished using SternaLock Blu plates and screws in combination with single-wire method of sternal reduction.
Study: NCT00764920

Intervention type: DEVICE
Intervention: non-invasive imaging modalities for assessment of skin
Description: skin imaging
Study: NCT00547118

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rimonabant
Description: One 20 mg tablet given 1 time per day for 112 days.
Study: NCT01812694

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Enhanced standard care
Description: Standard prenatal care plus education

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intensive lifestyle intervention
Description: Intervention to limit excess gestational weight gain
Study: NCT00547118

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: One placebo tablet given 1 time per day for 112 days.
Study: NCT01872052

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Acutus Medical System Mapping
Description: Mapping with the Acutus Medical System followed by intracardiac ablation of typical atrial flutter
Study: NCT00465231

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: bupivacaine, fentanyl
Description: 10mL of 0.0625% of bupivacaine plus fentanyl 2 mcg/ml
Study: NCT01335542

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Peri-Articular Injection
Description: Pre-operative anesthesia/analgesia: meloxicam (7.5 or 15mg), dexamethasone (6mg) Anesthetic:: Combined Spinal-Epidural with 0.5% bupivacaine. IV sedation with midazolam, propofol Antiemetic: 20mg famotidine, 4mg ondansetron Postoperative pain management: hydromorphone/bupivacaine PCEA (4/4/10/20, initially). Meloxicam (7.5 or 15mg), Oxycodone/Acetaminophen (5/325 3hr PRN)
Study: NCT00465231

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: preservative free saline
Description: 10mL saline solution
Study: NCT01908894

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIOD-123
Study: NCT01335542

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Epidural Pathway (PCEA+FNB)
Description: Pre-operative anesthesia/analgesia: meloxicam (7.5 or 15mg), extended release oxycodone (10mg or 20mg), dexamethasone (6mg), clonidine patch (100 mcg/24 hr) Anesthetic: Spinal with 0.5% bupivacaine, IV sedation with midazolam, propofol Antiemetic: 20mg famotidine, 4mg ondansetron Post-operative analgesia:Prilosec (20mg), Meloxicam (7.5mg or 15 mg PO), extended release oxycodone (10mg or 20mg), Oxycodone (5mg q 3 hr PRN), Acetaminophen (1000mg), ketorolac 15mg IV
Study: NCT01908894

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIOD-125
Study: NCT00347854

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Systane Free lubricant eye drops

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Visine Tears Lubricant Eye Drops

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Refresh Liquigel Lubricant Eye Drops
Study: NCT01958749

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Fat graft with Platelet Rich Plasma
Study: NCT00347854

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Refresh Plus Lubricant Eye Drops
Study: NCT01908894

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Humalog
Study: NCT03877120

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Dexmedetomidine 0.004 MG/ML
Description: Experimental studies and single case reports suggest the α2-agonist dexmedetomidine is effective in managing the autonomic symptoms seen with alcohol withdrawal.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Diazepam Injectable Solution
Description: diazepam start with 5-20 mg IV as a dose response, steps until a maximum dose of 120 mg diazepam.
Study: NCT01981967

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IMOJEV®: Live attenuated Japanese encephalitis chimeric virus vaccine
Description: 0.5 mL, Subcutaneous.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: IMOJEV®: Live attenuated Japanese encephalitis chimeric virus vaccine
Description: 0.5 mL, Subcutaneous.
Study: NCT02257684

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pegcrisantaspase